Search Results for "Metabolic"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Metabolic. Results 121 to 130 of 240 total matches.
Opill — An OTC Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
the metabolism of norgestrel and
decrease its effectiveness. Recent studies suggest
that concurrent use of non ...
The FDA has approved Opill (Perrigo), a progestin-only
oral contraceptive that contains norgestrel, for
sale over the counter (OTC). Opill is the first oral
contraceptive to be approved in the US for sale without
a prescription. Approval of OTC Opill is intended
to increase access to effective contraception and
reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2 doi:10.58347/tml.2023.1685c | Show Introduction Hide Introduction
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
single dose vials
Metabolism Minimal Minimal
Elimination Urine (75-85%) Urine (78%)
Half-life 2.15 ...
The FDA has approved Xacduro (Innoviva), a
combination of the beta-lactam antibacterial
sulbactam and the beta-lactamase inhibitor
durlobactam, for IV treatment of adults with hospital-acquired
or ventilator-associated bacterial pneumonia
caused by susceptible isolates of Acinetobacter
baumannii-calcoaceticus complex (ABC).
Med Lett Drugs Ther. 2023 Nov 27;65(1690):189-90 doi:10.58347/tml.2023.1690c | Show Introduction Hide Introduction
Tovorafenib (Ojemda) for Pediatric Low-Grade Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
Route Oral
Formulation 100 mg tablets, 25 mg/mL suspension
Tmax 3 hours
Metabolism Primarily ...
Tovorafenib (Ojemda – Day One), a type II RAF kinase
inhibitor, has received accelerated approval from the
FDA for treatment of patients ≥6 months old with
relapsed or refractory pediatric low-grade glioma
harboring a BRAF fusion or rearrangement or a BRAF
V600 mutation. Tovorafenib is the first systemic
treatment to be approved in the US for pediatric
low-grade gliomas with BRAF fusions. Accelerated
approval of tovorafenib was based on response rates
and duration of response.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):e97-8 doi:10.58347/tml.2024.1704f | Show Introduction Hide Introduction
Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025 (Issue 1723)
.
DRUG INTERACTIONS — DXd is metabolized primarily
by CYP3A4; coadministration with strong CYP3A4 ...
The FDA has approved datopotamab deruxtecan
(Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast
cell-surface antigen-2 (Trop-2)-directed antibody
and topoisomerase inhibitor conjugate, for treatment
of adults with unresectable or metastatic hormone
receptor (HR)-positive, human epidermal growth factor
receptor 2 (HER2)-negative breast cancer who received
prior endocrine-based therapy and chemotherapy for
unresectable or metastatic disease.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-2 doi:10.58347/tml.2025.1723e | Show Introduction Hide Introduction
Comparison Table: Some Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
are not significantly
metabolized by CYP isozymes and are less likely to interact with
other drugs
▶ Simvastatin ...
View the Comparison Table: Some Lipid-Lowering Drugs
Molnupiravir - An Oral Antiviral Drug for COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
with molnupiravir have been identified. It
is not metabolized by CYP450 isozymes and is only
minimally excreted ...
The investigational oral antiviral drug molnupiravir
(Merck/Ridgeback Biotherapeutics) was granted an
FDA Emergency Use Authorization (EUA) on December
23, 2021 for treatment of mild to moderate COVID-19
in outpatients ≥18 years old who are at high risk of
progressing to severe disease, including hospitalization
or death (see Table 1), and for whom alternative treatment options are
not available or clinically appropriate. Paxlovid (Pfizer),
nirmatrelvir copackaged with ritonavir, was granted
an EUA on December 22, 2021. The IV antiviral drug
remdesivir (Veklury) was approved by the...
Adagrasib (Krazati) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
family inhibitor
Formulation 200-mg tablets
Route Oral
Tmax ~6 hours
Metabolism Primarily by CYP3A4 ...
Adagrasib (Krazati – Mirati Therapeutics), a RAS
GTPase family inhibitor, has received accelerated
approval from the FDA for oral treatment of KRAS
G12C-mutated locally advanced or metastatic non-small
cell lung cancer (NSCLC) in adults who received
at least one prior systemic therapy. Accelerated
approval was based on the objective response rate
and duration of response.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e17-8 doi:10.58347/tml.2023.1668f | Show Introduction Hide Introduction
Epsolay - A Benzoyl Peroxide Cream for Rosacea
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
AND LACTATION — Topical benzoyl
peroxide is poorly absorbed and rapidly metabolized;
use by pregnant ...
Epsolay (Galderma), a 5% benzoyl peroxide cream,
has been approved by the FDA for treatment of
inflammatory lesions of rosacea in adults. It is the first
product containing benzoyl peroxide to be approved
in the US for treatment of rosacea. Benzoyl peroxide
formulations approved for acne have been used off-label
to treat rosacea for years, but itching and burning
have limited their use.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):21-2 doi:10.58347/tml.2023.1669c | Show Introduction Hide Introduction
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
Metabolism Endogenous degradation
Half-life 36.4 hours (in cycle 1 in breast cancer patients)
Table 2 ...
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously
called Rolontis), a granulocyte colony-stimulating
factor (G-CSF) conjugated to an Fc fragment of human
IgG4, has been approved by the FDA to decrease
the incidence of infection, as manifested by febrile
neutropenia, in adults with nonmyeloid malignancies
receiving myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia.
Med Lett Drugs Ther. 2023 May 29;65(1677):83-4 doi:10.58347/tml.2023.1677b | Show Introduction Hide Introduction
Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
capsules
Tmax ~2 hours
Metabolism CYP450 and non-CYP450
(sulfation and glucuronidation)
Elimination ...
Fruquintinib (Fruzaqla – Takeda), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with metastatic colorectal cancer (mCRC)
who received prior fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy, anti-VEGF therapy,
and, in patients with RAS wild-type mutations, anti-EGFR therapy. The drug can be used in patients with
mCRC regardless of biomarker status. Fruquintinib
is the first drug to become available in the US for
treatment of mCRC that targets 3 VEGF receptor
kinases.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e34-5 doi:10.58347/tml.2024.1696f | Show Introduction Hide Introduction